Nektar Therapeutics (NKTR)
35.78
-1.94
(-5.14%)
USD |
NASDAQ |
Oct 16, 16:00
35.76
-0.02
(-0.06%)
After-Hours: 20:00
Nektar Therapeutics Free Cash Flow : -234.03M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -234.03M |
| March 31, 2026 | -203.94M |
| December 31, 2025 | -208.68M |
| September 30, 2025 | -190.35M |
| June 30, 2025 | -186.07M |
| March 31, 2025 | -178.19M |
| December 31, 2024 | -177.18M |
| September 30, 2024 | -177.82M |
| June 30, 2024 | -175.37M |
| March 31, 2024 | -189.17M |
| December 31, 2023 | -193.47M |
| September 30, 2023 | -204.40M |
| June 30, 2023 | -245.32M |
| March 31, 2023 | -269.40M |
| December 31, 2022 | -309.68M |
| September 30, 2022 | -408.90M |
| June 30, 2022 | -429.91M |
| March 31, 2022 | -440.32M |
| December 31, 2021 | -427.65M |
| September 30, 2021 | -370.60M |
| June 30, 2021 | -321.12M |
| March 31, 2021 | -321.53M |
| December 31, 2020 | -320.54M |
| September 30, 2020 | -349.05M |
| June 30, 2020 | -368.43M |
| Date | Value |
|---|---|
| March 31, 2020 | -347.40M |
| December 31, 2019 | -354.97M |
| September 30, 2019 | -352.31M |
| June 30, 2019 | -351.58M |
| March 31, 2019 | 670.88M |
| December 31, 2018 | 703.98M |
| September 30, 2018 | 747.42M |
| June 30, 2018 | 912.79M |
| March 31, 2018 | -104.89M |
| December 31, 2017 | -90.09M |
| September 30, 2017 | -62.36M |
| June 30, 2017 | -182.36M |
| March 31, 2017 | -136.74M |
| December 31, 2016 | -123.42M |
| September 30, 2016 | -145.94M |
| June 30, 2016 | -136.24M |
| March 31, 2016 | -171.86M |
| December 31, 2015 | -84.28M |
| September 30, 2015 | -35.21M |
| June 30, 2015 | -63.94M |
| March 31, 2015 | -22.92M |
| December 31, 2014 | -151.98M |
| September 30, 2014 | -72.55M |
| June 30, 2014 | -45.94M |
| March 31, 2014 | -71.00M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Eli Lilly & Co. | 13.56B |
| Inovio Pharmaceuticals, Inc. | -80.78M |
| Tonix Pharmaceuticals Holding Corp. | -160.40M |
| Capricor Therapeutics, Inc. | -129.78M |
| Kyntra Bio, Inc. | -38.06M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -75.77M |
| Cash from Investing (Quarterly) | -399.11M |
| Cash from Financing (Quarterly) | 364.57M |
| Free Cash Flow Per Share (Quarterly) | -2.295 |
| Free Cash Flow to Equity (Quarterly) | -68.37M |
| Free Cash Flow to Firm (Quarterly) | -68.66M |
| Free Cash Flow Yield | -26.96% |